Delineation of biomarkers and molecular pathways of residual effects of fluoxetine treatment in juvenile rhesus monkeys by proteomic profiling

Fluoxetine (Prozac™) is the only antidepressant approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in children. Despite its considerable efficacy as a selective serotonin reuptake inhibitor, the possible long-term effects of fluoxetine on brain...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Yu, Park, Dong Ik, Horn, Anja, Golub, Mari, Turck, Christoph W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science Press 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841182/
https://www.ncbi.nlm.nih.gov/pubmed/36266933
http://dx.doi.org/10.24272/j.issn.2095-8137.2022.196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841182/
https://www.ncbi.nlm.nih.gov/pubmed/36266933
http://dx.doi.org/10.24272/j.issn.2095-8137.2022.196

Ejemplares similares